Aptargroup

AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions and services for the prescription drug, consumer health care, injectables, active packaging, beauty, personal care, home care, and food and beverages. It operates through the following business segments: Beauty & Home, Pharma and Food & Beverage. The Beauty & Home segment primarily sells pumps, aerosol valves and accessories to the personal care and household markets and pumps and decorative components to the fragrance/cosmetic market. The Pharma segment supplies pumps and metered dose inhaler valves to the pharmaceutical market worldwide. The Food & Beverage segment sells dispensing and non-dispensing closures and, to a lesser degree, spray pumps and aerosol valves to the food and beverage markets. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aptargroup (ATR) reports robust Q4 results and strategic realignment

Aptargroup's Q4 performance reflects strong core sales growth and profitability, driven by the pharma and beauty segments, despite regional challenges.
Realignment initiatives aim to optimize operations and enhance market position, with a focus on cost management and sustainable growth opportunities.
While facing challenges such as volume declines and increased expenses, Aptar remains poised for growth with a positive outlook for the year ahead.
The company's strategic focus on capital efficiencies, innovation, and sustainability underscores its commitment to long-term success and profitability.

Aptar reports solid Q1 growth driven by Pharma and Beauty demand

Aptar's Q1 performance reflects growth in key segments, with a positive outlook for Q2. Strategic focus on operational efficiencies and new product innovations positions the company for continued success.

Aptargroup (ATR) reports solid Q2 performance and optimistic growth outlook

Aptargroup's Q2 2023 performance showcased strength in core sales growth, robust segmental performance, and a focus on sustainability and shareholder value.
While facing challenges in certain operational areas, the company remains optimistic about future growth prospects and is committed to addressing hurdles effectively.
With a positive outlook for Q3 and a strategic focus on innovation and sustainability, Aptar is well-positioned to capitalize on growth opportunities and drive long-term value creation.

Aptargroup reports 2% sales growth in Q3 driven by Pharma success

Aptargroup's Q3 performance reflects solid sales growth and profitability, driven by strength in Pharma and fragrance technologies.
The company's emphasis on innovation, sustainability, and governance underscores its commitment to long-term success and stakeholder value.
Despite challenges in the Beauty segment, Aptar's strategic focus on growth opportunities and cost optimization positions it well for future success.

Aptargroup (ATR) reports solid Q4 earnings, eyes Asia expansion

Aptargroup's Q4 2023 performance reflects steady growth, strong margins, and strategic initiatives for future expansion. While facing challenges in certain segments, the company's focus on innovation and sustainability, along with successful partnerships, positions it well for continued growth. Shareholders benefited from over $104 million returned in 2023.

Aptargroup (ATR) reports robust Q1 results, eyes pharma growth opportunities

Aptargroup's Q1 performance reflects a balanced growth trajectory with strengths in sustainability recognition and product innovation. While challenges in the Beauty segment persist, opportunities in pharma growth and margin improvement are key focus areas for future success.

Aptargroup (ATR) reports solid Q2 results, eyes growth opportunities

Aptargroup's Q2 performance reflects resilience and strategic focus on core business segments amidst market challenges.
The company's financial strength, sustainability recognition, and leadership continuity position it well for future growth.
Challenges in injectables and Beauty segments underscore the need for targeted strategies and market adaptation.
Opportunities lie in innovation, market expansion, and leveraging sustainability efforts for competitive advantage.

Aptar reports robust Q3 performance driven by pharma and food

Aptar's Q3 2024 performance reflects solid core sales growth and increased EPS, driven by strong demand in pharma and food segments. Challenges in the Beauty segment were offset by growth in personal care and home care markets.
Key strengths include operational improvements, acquisitions in the Pharma segment, and recognition for corporate excellence. Aptar's focus on innovation and efficiency presents opportunities for future growth.
While facing challenges in the Beauty segment and CFO transition, Aptar remains optimistic about growth prospects in Pharma and Closures segments, emphasizing innovation and market opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AptarGroup, Inc. engages in the design, manufacture, drug delivery, consumer product dispensing, sealing and active packaging solutions, and services for the prescription drug, consumer health care, injectable, active packaging, beauty, personal care, home care, and food and beverages industries. It operates through the following segments: Pharma, Beauty and Home, and Food and Beverage. The company was founded in 1940 and is headquartered in Crystal Lake, IL.

CRYSTAL LAKE, III.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that following the signature of a share purchase agreement on July 22, 2021 and the approval of the French Ministry of Economy under the foreign investment clearance regulations, it has completed the acquisition of a majority stake in Voluntis (ENXTPA: ALVTX) from the company's reference shareholders and certain m

Aptar Announces the Completion of the Acquisition of a Majority Stake in Voluntis

AptarGroup's (ATR) second-quarter 2021 top line improves on increased demand for the company's dispensing solutions.

AptarGroup (ATR) Shares Decline as Q2 Earnings Lag Estimates

AptarGroup, Inc. (ATR) CEO Stephan Tanda on Q2 2021 Results - Earnings Call Transcript

AptarGroup Inc (NYSE: ATR) reported second-quarter FY21 sales growth of 15.9% year-on-year, to $811.03 million, beating the analyst consensus of $774.81 million. The Core sales, excluding currency effects, increased 10% on double-digit core growth in Beauty + Home and Food + Beverage, driven by increased demand for dispensing solutions and price adjustments.

AptarGroup Reports Mixed Q2 Results, Sees Q3 EPS Below Consensus

AptarGroup (ATR) delivered earnings and revenue surprises of -6.19% and 4.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AptarGroup (ATR) Q2 Earnings Lag Estimates

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today reported second quarter results for 2021. Second Quarter 2021 Summary Reported sales grew 16% driven by strong core sales growth and positive currency effects Core sales (excluding currency effects) increased 10% mainly on double digit core growth in Beauty + Home and Food + Beverage, driven by increased demand for our innov

Aptar Reports Second Quarter 2021 Results

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that it has entered into an agreement to acquire 80% of the equity interests of Weihai Hengyu Medical Products Co., Ltd., a leading Chinese manufacturer of elastomeric and plastic components used in injectable drug delivery. This acquisition supports Aptar's strategic priority to strengthen capabilities in high-gro

Aptar Enters into Agreement with Weihai Hengyu Medical Products to Add Elastomeric and Plastic Component Manufacturing Capabilities in China for Injectable Drug Delivery

AptarGroup (ATR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for AptarGroup (ATR)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions announced today that following the entry into exclusive negotiations with Voluntis (ENXTPA: ALVTX) on June 21, 2021, and after completion of the consultation procedure of the employee representative bodies of Voluntis, it has signed on July 22, 2021 a share purchase agreement for the acquisition of a majority stake in Voluntis, re

Aptar Announces the Signature of a Share Purchase Agreement Regarding the Acquisition of a Majority Stake in Voluntis at a Price of €8.70 Per Share

Alkermes

Pacer US Export Leaders ETF

ResMed

Standard Motor Products

Tempur Sealy International

Vanguard S&P Small-Cap 600 Growth ETF

As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.

7 Growth Stocks to Buy As Meme Stock Mania Fades

Berry Global Group

BERY vs. ATR: Which Stock Is the Better Value Option?

BERY vs. ATR: Which Stock Should Value Investors Buy Now?

Drug delivery devices manufacturer AptarGroup Inc (NYSE: ATR) is collaborating with YAT, a Chinese Online Skincare Company, to develop a range of products and services for the skincare market. The partnership will combine YAT's product design and concept development capabilities and Aptar's packaging and dispensing solutions.

AptarGroup Partners With Chinese Skincare Company YAT

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science, and YAT, a multi-functional, science-driven online skincare solutions company, have announced a strategic collaboration that aims to develop an innovative range of products and services for the skincare market. This partnership will bring together YAT's unique consumer centric, product design and concept development capabilities and Aptar'

Aptar Announces Strategic Collaboration with YAT, a Chinese Online Skincare Company, to Develop Range of Products and Services for the Skincare Market

AptarGroup's (ATR) plans to acquire Voluntis will help expand its digital healthcare offerings for chronic diseases as well as drive innovation.

AptarGroup (ATR) Eyeing Voluntis to Expand in Digital Therapeutics

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions announced today that it has entered into exclusive negotiations with respect to a potential acquisition of all outstanding shares of Voluntis (ENXTPA: ALVTX), a pioneer in digital therapeutics. This acquisition would complement Aptar's existing digital health portfolio of connected devices by adding digital therapeutic solutions a

Aptar Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital Therapeutics

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, today released its 2020 Corporate Sustainability Report. The 2020 Sustainability Report highlights Aptar's extensive sustainability initiatives that have been implemented across its global operations. As in previous reports, Aptar summarizes several milestones measured and achieved in three key areas of people, planet and product

Aptar Releases 2020 Corporate Sustainability Report

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announces the launch of the company's first fully recyclable mono-material pump for the beauty and personal care industries, called Future. Certified and Sustainable by Design In order to facilitate recycling, Future was designed using polyethylene (PE) mono-material only. Future is certified by Cyclos-HTP, the institute for Recyc

Aptar Introduces a Fully Recyclable Mono-Material Pump

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that Candace Matthews has joined its Board of Directors. Candace is a highly accomplished business leader with over 30 years of experience developing and marketing products for the healthcare, cosmetics, food and beverage industries. Candace currently serves as the Chief Reputation Officer for Amway, overseeing th

Aptar Appoints Candace Matthews to the Board of Directors

AptarGroup has an enviable position in the medical and beauty packaging sector.

AptarGroup: A Well-Managed But Expensive Specialty Packaging Company

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that it has been named to 3BL Media's 100 Best Corporate Citizens ranking for its leadership and transparency in environmental, social and governance (ESG). 3BL Media evaluated the 1,000 largest public U.S. companies on ESG and Aptar is among the top 50 companies in this ranking. “We are honored to be named among

Aptar Named Among the 100 Best Corporate Citizens of 2021

Investors can retain AptarGroup (ATR) stock in their portfolio for the time being on upbeat prospects.

Here's Why You Should Hold on to AptarGroup (ATR) Stock Now

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that it will increase prices five percent for its beauty, personal care and home care products. The price increases will take effect June 1, 2021 and will be in addition to any price adjustments related to raw material cost increases. The price adjustments are necessary due to sustained significant cost inflation o

Aptar Announces Price Increases

AptarGroup's (ATR) first-quarter results improve on increased demand for food dispensing closures and for dispensing systems used with sanitizers and cleaning products.

AptarGroup (ATR) Q1 Earnings Beat Estimates, Improve Y/Y

AptarGroup, Inc. (ATR) CEO Stephan Tanda on Q1 2021 Results - Earnings Call Transcript

AptarGroup (ATR) delivered earnings and revenue surprises of 21.11% and -0.98%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for Aptargroup Stock (ATR)